Last updated: February 21, 2026
What is NDC 00378-5186?
NDC 00378-5186 corresponds to Doxorubicin Hydrochloride Injection, a generic version of a chemotherapy drug used in treating various cancers, including breast cancer, bladder cancer, and certain lymphomas. It is marketed by generic manufacturers and is often part of combination chemotherapies.
Market Overview
Market Size and Demand
- The global oncology market was valued at approximately $201 billion in 2022, projected to reach $310 billion by 2027 with a compound annual growth rate (CAGR) of 8.7%[1].
-
Doxorubicin formulations, including the injection under NDC 00378-5186, represent a significant segment within this market, primarily driven by:
-
Rising cancer incidence rates worldwide.
-
Increased adoption of chemotherapy regimens.
-
Healthcare provider preference for established generic options.
Competitive Landscape
- Major suppliers include Teva Pharmaceuticals, Pfizer (BioNTech’s proprietary formulations), and Sagent Pharmaceuticals.
- The patent expiration timeline for branded doxorubicin drugs occurred around 2010-2015, opening the market to generics.
- The generic market share for doxorubicin products exceeds 60% due to lower prices and wide availability[2].
Regulatory and Reimbursement Factors
- The FDA registered the generic under Controlled Substances Act regulations.
- Reimbursement policies favor generics. Medicare and Medicaid reimbursements are set close to acquisition costs, incentivizing hospitals and clinics to favor low-cost options.
- Price discounts for hospital purchase programs exist, influencing wholesale and retail pricing.
Price Projections
Current Pricing and Historical Trends
| Price Metric |
2022 Average Wholesale Price (AWP) |
2023 Expected Price Range |
Source |
| Vial (per 20 mg) |
$80 - $110 |
$75 - $105 |
[3][4] |
| Small-volume packages |
$200 - $300 (per 50 mL vial) |
$190 - $290 |
[3][4] |
- The AWP for the 20 mg vial has declined approximately 10-15% since patent expiry, with further modest reductions expected due to increased generic competition.
Future Price Trends
-
Price reductions are likely to stabilize or slightly decline over the next five years, driven by:
-
Market saturation.
-
Cost pressures from hospital procurement.
-
Entry of biosimilars, if approved, though none exist for doxorubicin as of 2023.
-
Wholesale Acquisition Cost (WAC) will hover around $70-$100 per 20 mg vial by 2026.
Price Influences
- Manufacturing costs for bulk injectable drugs approximate $10-$15 per vial[5], but pricing depends on distribution, insurance contracts, and hospital procurement negotiations.
- Pricing can vary regionally and based on volume discounts.
Key Takeaways
- The NDC 00378-5186 market is stable with a high share of generics.
- Prices have declined since patent expirations, aligning with market competition.
- Future prices will likely trend slightly downward or stabilize around current levels, with minimal impact expected from biosНеids or new formulations.
- Demand remains driven by the global increase in cancer cases and standard chemotherapy protocols.
- Competitive pressure from hospital procurement and reimbursement policies keeps prices low.
FAQs
1. What is the primary use of NDC 00378-5186?
It is used as a chemotherapy agent in treating cancers including breast, bladder, and lymphomas.
2. How does generic competition impact prices?
It drives prices downward, restricting profit margins for manufacturers, especially when multiple suppliers operate.
3. Are biosimilars a concern for this drug?
No, biosimilars are not yet approved for doxorubicin, but future regulatory developments could change this.
4. How do procurement policies influence price?
Hospitals and payers prefer low-cost options, leading to volume-based discounts and lower overall pricing.
5. What factors could alter future pricing?
Manufacturing cost changes, regulatory shifts, new competing therapies, and supply chain disruptions.
References
[1] Grand View Research. (2022). Oncology Drugs Market Size, Trends & Forecast.
[2] IQVIA. (2021). Prescription Drug Market Share and Competitive Dynamics.
[3] Red Book. (2023). Pharmaceutical Pricing Data.
[4] SSR Health. (2023). GPI (Generic Price Index) Reports.
[5] U.S. Food and Drug Administration. (2022). Drug Manufacturing Cost Analysis.
Note: All data and projections are estimates based on current market conditions and may vary with future market changes.
